Superworth

Larimar Therapeutics revenue LRMR

Sales by quarter and over the last twelve months, from 2013.

Last 12 months, to Mar 31, 2020
$0
Latest quarter, Q1 FY20
$0
Fiscal year 2019
$0

Larimar Therapeutics' revenue was $0 over the twelve months to Mar 31, 2020.

In its latest quarter, Q1 FY20, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2019$0n/a
FY2018$0n/a
FY2017$0n/a
FY2016$0n/a
FY2015$0n/a
FY2014$0n/a
FY2013$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY20$0n/a$0
Q4 FY19$0n/a$0
Q3 FY19$0n/a$0
Q2 FY19$0n/a$0
Q1 FY19$0n/a$0
Q4 FY18$0n/a$0
Q3 FY18$0n/a$0
Q2 FY18$0n/a$0
Q1 FY18$0n/a$0
Q4 FY17$0n/a$0
Q3 FY17$0n/a$0
Q2 FY17$0n/a$0

Against its peers

Companies in Drug Manufacturers - General nearest Larimar Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
LRMRLarimar Therapeuticsn/m
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
LFVNLifevantage$182.6M−20% a year
ABUSArbutus Biopharma$181.7M
SPROSpero Therapeutics$47M−3% a year
Peer median$274M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Larimar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.